Tag: normal-pressure hydrocephalus
Cerevasc secures US$70 million financing following US FDA approval of STRIDE...
Cerevasc announced recently that it has successfully completed the initial closing of a US$70 million Series B financing, which was jointly led by Bain Capital Life...
Cerevasc announces US FDA-approved expansion of normal-pressure hydrocephalus study
Cerevasc has announced that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) supplement to permit the expansion of...
CereVasc announces first treatment in US trial evaluating eShunt for normal-pressure...
CereVasc today announced completion of the first eShunt procedure in the USA as part of a pilot study involving normal-pressure hydrocephalus (NPH) patients.
The study is being conducted...
First patient treated in clinical trial of CereVasc’s eShunt system for...
CereVasc has announced treatment of the first patient in its clinical study of the eShunt system in patients with normal-pressure hydrocephalus (NPH).
Following approval from Argentina's...
CereVasc receives FDA nod to study eShunt system in normal-pressure hydrocephalus...
CereVasc has announced that the US Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate a pilot trial...
